How to buy Moderna shares

In mid November, US drugmaker Moderna announced its experimental COVID-19 vaccine was 94.5% effective in preventing the virus. The news comes just a week after Pfizer's vaccine revealed a 90% accuracy rate.

Moderna, Inc is a biotechnology business with stocks listed in the US. Moderna shares (MRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$148.38 – a decrease of 15.09% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Moderna

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for Moderna. Find the share by name or ticker symbol: MRNA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Moderna reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of US$148.38, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Moderna, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Moderna. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

US stocks

eToro Share Trading (US stocks)

Finder Award

Our top pick for

Cheap broker fees

IG Share Trading

Finder Award

Our top pick for

Long-term investing

CMC Markets Stockbroking

Finder Award

Moderna share price

Compare share trading platforms to buy stock

Sort by:

Name	Product	Standard brokerage for US shares	Inactivity fee	Currency conversion fee	Markets
eToro Share Trading (US stocks) Finder Award		US$0	US$10 per month if there’s been no login for 12 months	0.50%	US shares	Zero brokerage share trading on US stocks with trades as low as $50. Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.	Go to site More Info	Compare	loading Fetching your data...
IG Share Trading Finder Award		US$0	$50 per quarter if you make fewer than three trades in that period	0.70%	ASX shares, Global shares	$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares. Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.	Go to site More Info	Compare	loading Fetching your data...
CMC Markets Stockbroking Finder Award		US$0	No	0.60%	ASX shares, Global shares, mFunds, ETFs	$0 brokerage on global shares including US, UK and Japan markets. Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.	Go to site More Info	Compare	loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

Is it a good time to buy Moderna stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Shorting Moderna shares

There are currently 13.0 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 13.5% down from 15.0 million last month.

There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.

Moderna's "short interest ratio" (SIR)

Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 8.9 million). Moderna's SIR currently stands at 1.45. In other words for every 100,000 Moderna shares traded daily on the market, roughly 1450 shares are currently held short.

However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 30 shares are currently held short) or 0.0443% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 44 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.

Find out more about how you can short Moderna stock.

Moderna share dividends

We're not expecting Moderna to pay a dividend over the next 12 months.

Moderna share price volatility

Over the last 12 months, Moderna's shares have ranged in value from as little as US$43.11 up to US$189.26. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.377. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Moderna overview

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., and Recipharm for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Moderna is owned by insiders or institutions?

  Currently 9.746% of Moderna shares are held by insiders and 54.203% by institutions.

• When does the fiscal year end for Moderna?

  Moderna's fiscal year ends in December.

• Where is Moderna based?

  Moderna's address is: 200 Technology Square, Cambridge, MA, United States, 02139

• What is Moderna's ISIN number?

  Moderna's international securities identification number is: US60770K1079

• What is Moderna's CUSIP number?

  Moderna's Committee on Uniform Securities Identification Procedures number is: 56804Q201